The Environmental Cost Of Production: Will Big Pharma Be On The Hook For API Hazards?
This article was originally published in PharmAsia News
Executive Summary
Many companies source their active pharmaceutical ingredients from India and China to cut costs, but well-publicized reports of environmental hazards around these API facilities are adding additional costs and raising ethical and safety concerns, and regulators are weighing options to control the environmental impact of drug production